Trial Profile
A non-interventional observational study in adults and children from 5 years of age assessing the safety and tolerability of GRAZAX in case of concomitant specific immunotherapy (SCIT or SLIT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Timothy grass pollen allergen extract (Grastek) (Primary) ; Immunotherapies
- Indications Grass pollen hypersensitivity
- Focus Adverse reactions
- Sponsors ALK-Abello
- 20 May 2014 Status changed from recruiting to completed.
- 10 Jun 2013 New trial record